Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets.

Small-molecule-induced protein degradation has beendemonstrated to possess the potential to drug a broader range of proteinaceousbiological targets. It involves the selective recruitment of the body’sinherent protein degradation pathways, to eliminate disease causing /associated proteins, using bifunctional small molecule drugs. Presently, themost popular and promising class of interventions in this field of research, isproteolysis targeting chimeras (PROTACs); these can simultaneously bind atarget protein and an E3-ubiquitin ligase, and thereby, facilitate theselective ubiquitination and eventual proteasome-mediated degradation of thetarget protein. The most interesting feature of this mechanism of drug actionis the fact that PROTACs and other targeted protein degraders can eliminateprotein targets regardless of their function.


To order this 330+page report, which features 115+ figures and 180+ tables, please visit this link


The USD 3.3billion (by 2030) financial opportunity within the targeted protein degradationenabling technologies market has been analyzed across the following segments:

§ Type of Payment

§ Upfront Payment

§ Milestone Payment


§ Types of ProteinDegraders

§ Degronimids



§ Specific BET and DUBInhibitors

§ Other Inhibitors


§ Therapeutic Areas

  • Oncological Disorders
  • Neurological Disorders
  • Others


§ Route of Administration

§ Oral

§ Intravenous

§ Others


§ Key GeographicalRegions 

§ North America

§ Europe

§ Asia-Pacific


The Targeted Protein Degradation Market,2021-2030 report features thefollowing companies, which we identified to be key players in this domain:

§ Arvinas

§ AstraZeneca

§ BioTheryX

§ C4 Therapeutics

§ Captor Therapeutics

§ Celgene

§ Genentech

§ Hinova Pharmaceuticals

§ Kangpu Biopharmaceuticals

§ Kymera Therapeutics

§ Mission Therapeutics

§ Progenra

§ Radius Health

§ Sanofi Genzyme

§ Zenopharm


Table of Contents


1. Preface

2. Executive Summary

3. Introduction

1.    CurrentMarket Landscape: Target Protein Degradation-Based Therapeutics

5. Current Market Landscape: Target Protein DegradationEnabling Technologies

6. Company Profiles

7. Clinical Trial Analysis 

8. Academic Grants Analysis

9. Publication Analysis


10. Patent Analysis

11. KOL Analysis

12. Partnerships and Collaborations

13. Funding and Investment Analysis

14. Market Sizing and Opportunity Analysis


15. Licensing Deal Structure


16. Executive Insights


17. Concluding Remarks


18. Appendix 1: Tabulated Data


19. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415